Profund Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD

Profund Advisors LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the third quarter, Holdings Channel reports. The firm owned 120,129 shares of the biopharmaceutical company’s stock after selling 5,818 shares during the period. Profund Advisors LLC’s holdings in Gilead Sciences were worth $13,334,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. GoalVest Advisory LLC boosted its position in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the second quarter valued at $27,000. Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the second quarter worth about $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 373,037 shares of company stock worth $50,731,512 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $152.50 on Monday. The company has a fifty day simple moving average of $127.38 and a 200-day simple moving average of $121.04. The firm has a market capitalization of $189.20 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.80 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $153.13.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GILD. Daiwa Securities Group lifted their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Leerink Partners boosted their price objective on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Finally, Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $136.73.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.